New biomarker could hasten autism diagnoses

Researchers may have identified a new biomarker that can help diagnose autism spectrum disorder in some children, according to a study published in Biological Psychiatry.

Researchers with University of California-Davis Health and NeuroPointDX recently tested whether the dysregulation of amino acids was a pervasive phenomenon in individuals with autism.

According to the study, the research was a part of the Children’s Autism Metabolome Project (CAMP), which is a large-scale effort to define autism biomarkers based on metabolomic analyses of blood samples from young children. Currently, there are no “reliable” biomarkers to detect autism.

Plasma metabolites from 516 children with autism were compared to those from 164 typically-developed children. Researchers found that autism-associated amino acids dysregulation metabotypes (AADM) were present in 16.7 percent of the children with autism.

“The combination of glutamine, glycine and ornithine AADMs identified a dysregulation in amino acids/branch chain amino acids metabolism that is present in 16.7 percent of the CAMP (autistic) subjects and is detectable with a specificity of 96.3 percent and a (positive predictive value) of 93.5 percent,” the authors wrote.

Researchers believe the findings could help enable earlier diagnosis and generate targeted interventions for specific autism groups, according to a release.

“The long-term vision is, once we’ve been able to analyze all the data from CAMP, we would have a series of panels,” David Amaral, founding director of research at the MIND Institute and lead author of the study, said in a statement. “Each of these would be able to detect a subset of kids with autism. Ultimately, metabolomics may be able to identify most children with autism.”

""

Danielle covers Clinical Innovation & Technology as a senior news writer for TriMed Media. Previously, she worked as a news reporter in northeast Missouri and earned a journalism degree from the University of Illinois at Urbana-Champaign. She's also a huge fan of the Chicago Cubs, Bears and Bulls. 

Around the web

Compensation for heart specialists continues to climb. What does this say about cardiology as a whole? Could private equity's rising influence bring about change? We spoke to MedAxiom CEO Jerry Blackwell, MD, MBA, a veteran cardiologist himself, to learn more.

The American College of Cardiology has shared its perspective on new CMS payment policies, highlighting revenue concerns while providing key details for cardiologists and other cardiology professionals. 

As debate simmers over how best to regulate AI, experts continue to offer guidance on where to start, how to proceed and what to emphasize. A new resource models its recommendations on what its authors call the “SETO Loop.”